New antibody shows promise against dengue in early trial
NCT ID NCT06799741
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new drug called AV-1, which is a lab-made antibody, to see if it can prevent or treat dengue virus type 3 infection. Eighty-five healthy adults received either a low, medium, or high dose of AV-1 or a placebo, and were then exposed to a controlled dengue virus. Researchers measured safety, side effects, and how well the drug blocked the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AV-1 (a lab-made antibody given by IV)
What this could lead to
If it works, this could point toward a preventive treatment for dengue, a serious mosquito-borne disease.
What could go wrong
This is an early-phase trial with only 85 healthy adults, not patients. The results may not apply to real-world dengue infections, and the antibody may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENV-3 CONTROLLED HUMAN INFECTION MODEL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Immunization Research (CIR) JHBSPH
Baltimore, Maryland, 21205, United States
-
Center for Immunization Research Inpatient Unit
Baltimore, Maryland, 21224, United States
-
UVM Larner College of Medicine Department of MMG
Burlington, Vermont, 05405, United States